Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | The prognostic impact of secondary-type mutations in patients with favorable risk AML

Dimitrios Kotsos • 15 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia

Dimitrios Kotsos, MD, Erasmus MC, Rotterdam, Netherlands, discusses the prognostic impact of secondary-type mutations in patients with acute myeloid leukemia (AML) who are considered favorable risk according to the European LeukemiaNe (ELN) 2022 risk classification guidelines. This study found that these patients had lower complete remission (CR) and overall survival (OS) rates than patients without secondary-type mutations. However, this was only true for patients aged over 60. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Dimitrios Kotsos

AutoSCT versus consolidation chemotherapy as post-remission treatment in newly diagnosed AML
2:19
AutoSCT versus consolidation chemotherapy as post-remission treatment in newly diagnosed AML
Dimitrios Kotsos • 6 Dec 2025
CPX-351 versus intensive induction chemo in pts with tAML or AML with myelodysplasia-related changes
1:42
CPX-351 versus intensive induction chemo in pts with tAML or AML with myelodysplasia-related changes
Dimitrios Kotsos • 24 Jun 2024

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals